Cargando…

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Alleva, David G., Delpero, Andrea R., Scully, Melanie M., Murikipudi, Sylaja, Ragupathy, Ramya, Greaves, Emma K., Sathiyaseelan, Thillainaygam, Haworth, Jeffrey R., Shah, Nishit J., Rao, Vidhya, Nagre, Shashikant, Lancaster, Thomas M., Webb, Sarah S., Jasa, Allison I., Ronca, Shannon E., Green, Freedom M., Elyard, Hanne Andersen, Yee, JoAnn, Klein, Jeffrey, Karnes, Larry, Sollie, Frans, Zion, Todd C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491978/
https://www.ncbi.nlm.nih.gov/pubmed/34642088
http://dx.doi.org/10.1016/j.vaccine.2021.09.077
_version_ 1784578841711214592
author Alleva, David G.
Delpero, Andrea R.
Scully, Melanie M.
Murikipudi, Sylaja
Ragupathy, Ramya
Greaves, Emma K.
Sathiyaseelan, Thillainaygam
Haworth, Jeffrey R.
Shah, Nishit J.
Rao, Vidhya
Nagre, Shashikant
Lancaster, Thomas M.
Webb, Sarah S.
Jasa, Allison I.
Ronca, Shannon E.
Green, Freedom M.
Elyard, Hanne Andersen
Yee, JoAnn
Klein, Jeffrey
Karnes, Larry
Sollie, Frans
Zion, Todd C.
author_facet Alleva, David G.
Delpero, Andrea R.
Scully, Melanie M.
Murikipudi, Sylaja
Ragupathy, Ramya
Greaves, Emma K.
Sathiyaseelan, Thillainaygam
Haworth, Jeffrey R.
Shah, Nishit J.
Rao, Vidhya
Nagre, Shashikant
Lancaster, Thomas M.
Webb, Sarah S.
Jasa, Allison I.
Ronca, Shannon E.
Green, Freedom M.
Elyard, Hanne Andersen
Yee, JoAnn
Klein, Jeffrey
Karnes, Larry
Sollie, Frans
Zion, Todd C.
author_sort Alleva, David G.
collection PubMed
description AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain.
format Online
Article
Text
id pubmed-8491978
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-84919782021-10-06 Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452 Alleva, David G. Delpero, Andrea R. Scully, Melanie M. Murikipudi, Sylaja Ragupathy, Ramya Greaves, Emma K. Sathiyaseelan, Thillainaygam Haworth, Jeffrey R. Shah, Nishit J. Rao, Vidhya Nagre, Shashikant Lancaster, Thomas M. Webb, Sarah S. Jasa, Allison I. Ronca, Shannon E. Green, Freedom M. Elyard, Hanne Andersen Yee, JoAnn Klein, Jeffrey Karnes, Larry Sollie, Frans Zion, Todd C. Vaccine Article AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. The Authors. Published by Elsevier Ltd. 2021-10-29 2021-10-05 /pmc/articles/PMC8491978/ /pubmed/34642088 http://dx.doi.org/10.1016/j.vaccine.2021.09.077 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Alleva, David G.
Delpero, Andrea R.
Scully, Melanie M.
Murikipudi, Sylaja
Ragupathy, Ramya
Greaves, Emma K.
Sathiyaseelan, Thillainaygam
Haworth, Jeffrey R.
Shah, Nishit J.
Rao, Vidhya
Nagre, Shashikant
Lancaster, Thomas M.
Webb, Sarah S.
Jasa, Allison I.
Ronca, Shannon E.
Green, Freedom M.
Elyard, Hanne Andersen
Yee, JoAnn
Klein, Jeffrey
Karnes, Larry
Sollie, Frans
Zion, Todd C.
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
title Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
title_full Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
title_fullStr Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
title_full_unstemmed Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
title_short Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
title_sort development of an igg-fc fusion covid-19 subunit vaccine, aks-452
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491978/
https://www.ncbi.nlm.nih.gov/pubmed/34642088
http://dx.doi.org/10.1016/j.vaccine.2021.09.077
work_keys_str_mv AT allevadavidg developmentofaniggfcfusioncovid19subunitvaccineaks452
AT delperoandrear developmentofaniggfcfusioncovid19subunitvaccineaks452
AT scullymelaniem developmentofaniggfcfusioncovid19subunitvaccineaks452
AT murikipudisylaja developmentofaniggfcfusioncovid19subunitvaccineaks452
AT ragupathyramya developmentofaniggfcfusioncovid19subunitvaccineaks452
AT greavesemmak developmentofaniggfcfusioncovid19subunitvaccineaks452
AT sathiyaseelanthillainaygam developmentofaniggfcfusioncovid19subunitvaccineaks452
AT haworthjeffreyr developmentofaniggfcfusioncovid19subunitvaccineaks452
AT shahnishitj developmentofaniggfcfusioncovid19subunitvaccineaks452
AT raovidhya developmentofaniggfcfusioncovid19subunitvaccineaks452
AT nagreshashikant developmentofaniggfcfusioncovid19subunitvaccineaks452
AT lancasterthomasm developmentofaniggfcfusioncovid19subunitvaccineaks452
AT webbsarahs developmentofaniggfcfusioncovid19subunitvaccineaks452
AT jasaallisoni developmentofaniggfcfusioncovid19subunitvaccineaks452
AT roncashannone developmentofaniggfcfusioncovid19subunitvaccineaks452
AT greenfreedomm developmentofaniggfcfusioncovid19subunitvaccineaks452
AT elyardhanneandersen developmentofaniggfcfusioncovid19subunitvaccineaks452
AT yeejoann developmentofaniggfcfusioncovid19subunitvaccineaks452
AT kleinjeffrey developmentofaniggfcfusioncovid19subunitvaccineaks452
AT karneslarry developmentofaniggfcfusioncovid19subunitvaccineaks452
AT solliefrans developmentofaniggfcfusioncovid19subunitvaccineaks452
AT ziontoddc developmentofaniggfcfusioncovid19subunitvaccineaks452